Mongersen, an oral Smad7 antisense oligonucleotide, in patients with active Crohn's disease

Area of Science:

• Gastroenterology and Immunology
• Molecular Medicine
• Drug Development

Background:

• Crohn's disease (CD) involves sustained, tissue-damaging inflammation due to impaired counter-regulatory mechanisms.
• Elevated Smad7 levels in inflamed CD gut inhibit the crucial anti-inflammatory and repair factor, transforming growth factor-beta1 (TGF-β1).
• Smad7 acts as a key mediator in the pathogenesis of inflammatory bowel disease.

Purpose of the Study:

• To review the pathogenic role of Smad7 in Crohn's disease.
• To discuss the therapeutic potential of Smad7 inhibition using mongersen.
• To summarize clinical trial data on mongersen's efficacy and safety in CD patients.

Main Methods:

• Utilized an antisense oligonucleotide (mongersen) to specifically target and reduce Smad7 expression.
• Investigated the restoration of TGF-β1 activity following Smad7 knockdown.
• Reviewed data from Phase I and II clinical trials involving oral mongersen administration in active CD patients.

Main Results:

• Smad7 knockdown by mongersen restored TGF-β1 activity, suppressing inflammatory pathways.
• Mongersen treatment led to the resolution of colitis in preclinical models (mice).
• Oral administration of mongersen induced clinical remission in patients with active Crohn's disease.

Conclusions:

• Smad7 plays a significant pathogenic role in Crohn's disease.
• Mongersen represents a promising therapeutic strategy for Crohn's disease by targeting Smad7.
• Clinical trials indicate mongersen is effective and safe for inducing remission in CD patients.